Clinical Findings on High-Dose Nusinersen Published
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy BIIB?
Source: Newsfilter
- Clinical Study Results: Biogen's DEVOTE study results indicate that the high-dose nusinersen (50 mg and 28 mg) demonstrates significant safety and efficacy in spinal muscular atrophy (SMA) patients, particularly in treatment-naïve infants, with a mean difference of 26.19 points in motor function improvement, p<0.0001, highlighting its clinical potential.
- Neurodegeneration Biomarker Improvement: The high-dose regimen significantly accelerated the reduction of neurofilament, a marker of neurodegeneration, suggesting its advantage in slowing disease progression, which could reshape treatment strategies for SMA and enhance patient quality of life.
- FDA Review Progress: The high-dose nusinersen is currently under review by the U.S. FDA, with a decision expected by April 3, 2026, potentially providing patients with a more effective treatment option and further solidifying Biogen's leadership in the SMA treatment landscape.
- Positive Feedback from Diverse Patient Groups: In the open-label part of the DEVOTE study, 40 participants showed mean increases of 1.8 points on the Hammersmith Functional Motor Scale and 1.2 points on the Revised Upper Limb Module after transitioning to the high-dose regimen, demonstrating broad applicability across different ages and disease stages, boosting Biogen's confidence in future market opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
25 Analyst Rating
11 Buy
13 Hold
1 Sell
Moderate Buy
Current: 185.360
Low
135.00
Averages
186.19
High
250.00
Current: 185.360
Low
135.00
Averages
186.19
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Reports 2025 Earnings Exceeding Expectations
- Strong Financial Performance: Biogen's 2025 earnings report revealed total revenue of $2.28 billion, down 7% year-over-year, yet surpassing analyst expectations of $2.21 billion, indicating resilience amid challenges.
- Significant Net Income Decline: The company's non-GAAP net income fell sharply to $294 million ($1.99 per share) from over $502 million a year ago, reflecting increased market competition impacting profitability.
- Product Revenue Decline: Product revenue decreased by 9% to $1.67 billion, with multiple sclerosis treatment sales dropping 14% year-over-year to $917 million, highlighting the competitive pressure from generics and biosimilars.
- Positive Future Outlook: Biogen anticipates mid-single-digit revenue decline for 2026, with adjusted net income projected between $15.25 and $16.25 billion, exceeding the average analyst estimate of $14.92 billion, showcasing potential in new drug development and market expansion.
See More
Biogen's 2025 Financials Exceed Expectations
- Strong Financial Performance: Biogen's Q4 2025 report revealed total revenue of nearly $2.28 billion, down 7% year-over-year, yet surpassing analyst expectations of $2.21 billion, demonstrating the company's resilience in challenging market conditions.
- Declining Net Income: Non-GAAP net income fell to $294 million ($1.99 per share), a significant drop from over $502 million a year ago, reflecting increased competitive pressures impacting profitability.
- Product Revenue Decline: Product revenue decreased by 9% to $1.67 billion, with the largest drug category, multiple sclerosis (MS) treatments, experiencing a 14% year-over-year decline to $917 million, highlighting the impact of generics and biosimilars on sales.
- Positive 2026 Outlook: Biogen anticipates mid-single-digit revenue decline for 2026, with adjusted net income projected between $15.25 and $16.25 billion, exceeding the average analyst estimate of $14.92 billion, indicating growth potential in its new product lines.
See More
Biogen Inc. Reports Strong Q4 2025 Earnings with Growth Products Driving Revenue
- Performance Exceeds Expectations: Biogen reported a non-GAAP diluted EPS of $1.99 for Q4 2025 and $15.28 for the full year, both surpassing expectations, indicating strong growth from its new product portfolio and market performance, with total revenue reaching $9.9 billion, up 2% year-over-year.
- Growth Product Success: The company’s growth products generated $3.3 billion in revenue for 2025, a 19% increase, with Q4 contributing $800 million, demonstrating significant market acceptance of new products like VUMERITY and LEQEMBI, thereby enhancing the company's competitive position.
- Significant Pipeline Progress: Management highlighted the pipeline advancements as the
See More
Biogen Reports Strong Earnings, Optimistic Outlook Ahead
- Revenue Beat: Biogen reported fiscal 2025 revenues of $2.28 billion, surpassing the consensus estimate of $2.20 billion, despite a 7% year-over-year decline, demonstrating resilience amid market challenges.
- Strong Growth Products: Revenue from growth products increased by 19% year-over-year, successfully offsetting declines in multiple sclerosis product revenues, indicating effective strategies in drug development and market promotion.
- Market Performance: Leqembi collaboration revenue reached $47 million, with in-market sales of approximately $134 million, up 54%, reflecting strong demand for the Alzheimer's drug in the market.
- Optimistic Outlook: Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, exceeding the consensus of $14.92, and while multiple sclerosis product revenues are projected to decline, increases in growth product revenues are expected to partially offset this impact.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Biogen Q4 Earnings Beat Expectations
- Earnings Performance: Biogen reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company’s Q4 revenue of $2.28 billion represents a 7.3% year-over-year decline, yet it surpassed expectations by $80 million, showcasing resilience amid market pressures.
- 2026 Financial Guidance: Biogen anticipates a Non-GAAP diluted EPS for 2026 between $15.25 and $16.25, exceeding the consensus estimate of $14.95, reflecting confidence in future profitability.
- Revenue Outlook Adjustment: Although total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, this outlook is more conservative than the estimated -5.11% growth, indicating prudent financial management.
See More
Biogen Reports 2025 Earnings Exceeding Expectations
- Strong Financial Performance: Biogen's 2025 earnings report revealed total revenue of $2.28 billion, down 7% year-over-year, yet surpassing analyst expectations of $2.21 billion, indicating resilience amid challenges.
- Significant Net Income Decline: The company's non-GAAP net income fell sharply to $294 million ($1.99 per share) from over $502 million a year ago, reflecting increased market competition impacting profitability.
- Product Revenue Decline: Product revenue decreased by 9% to $1.67 billion, with multiple sclerosis treatment sales dropping 14% year-over-year to $917 million, highlighting the competitive pressure from generics and biosimilars.
- Positive Future Outlook: Biogen anticipates mid-single-digit revenue decline for 2026, with adjusted net income projected between $15.25 and $16.25 billion, exceeding the average analyst estimate of $14.92 billion, showcasing potential in new drug development and market expansion.
See More
Biogen's 2025 Financials Exceed Expectations
- Strong Financial Performance: Biogen's Q4 2025 report revealed total revenue of nearly $2.28 billion, down 7% year-over-year, yet surpassing analyst expectations of $2.21 billion, demonstrating the company's resilience in challenging market conditions.
- Declining Net Income: Non-GAAP net income fell to $294 million ($1.99 per share), a significant drop from over $502 million a year ago, reflecting increased competitive pressures impacting profitability.
- Product Revenue Decline: Product revenue decreased by 9% to $1.67 billion, with the largest drug category, multiple sclerosis (MS) treatments, experiencing a 14% year-over-year decline to $917 million, highlighting the impact of generics and biosimilars on sales.
- Positive 2026 Outlook: Biogen anticipates mid-single-digit revenue decline for 2026, with adjusted net income projected between $15.25 and $16.25 billion, exceeding the average analyst estimate of $14.92 billion, indicating growth potential in its new product lines.
See More
Biogen Inc. Reports Strong Q4 2025 Earnings with Growth Products Driving Revenue
- Performance Exceeds Expectations: Biogen reported a non-GAAP diluted EPS of $1.99 for Q4 2025 and $15.28 for the full year, both surpassing expectations, indicating strong growth from its new product portfolio and market performance, with total revenue reaching $9.9 billion, up 2% year-over-year.
- Growth Product Success: The company’s growth products generated $3.3 billion in revenue for 2025, a 19% increase, with Q4 contributing $800 million, demonstrating significant market acceptance of new products like VUMERITY and LEQEMBI, thereby enhancing the company's competitive position.
- Significant Pipeline Progress: Management highlighted the pipeline advancements as the
See More
Biogen Reports Strong Earnings, Optimistic Outlook Ahead
- Revenue Beat: Biogen reported fiscal 2025 revenues of $2.28 billion, surpassing the consensus estimate of $2.20 billion, despite a 7% year-over-year decline, demonstrating resilience amid market challenges.
- Strong Growth Products: Revenue from growth products increased by 19% year-over-year, successfully offsetting declines in multiple sclerosis product revenues, indicating effective strategies in drug development and market promotion.
- Market Performance: Leqembi collaboration revenue reached $47 million, with in-market sales of approximately $134 million, up 54%, reflecting strong demand for the Alzheimer's drug in the market.
- Optimistic Outlook: Biogen expects fiscal 2026 earnings between $15.25 and $16.25 per share, exceeding the consensus of $14.92, and while multiple sclerosis product revenues are projected to decline, increases in growth product revenues are expected to partially offset this impact.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Biogen Q4 Earnings Beat Expectations
- Earnings Performance: Biogen reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company’s Q4 revenue of $2.28 billion represents a 7.3% year-over-year decline, yet it surpassed expectations by $80 million, showcasing resilience amid market pressures.
- 2026 Financial Guidance: Biogen anticipates a Non-GAAP diluted EPS for 2026 between $15.25 and $16.25, exceeding the consensus estimate of $14.95, reflecting confidence in future profitability.
- Revenue Outlook Adjustment: Although total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, this outlook is more conservative than the estimated -5.11% growth, indicating prudent financial management.
See More
